Skip to main content

Advertisement

Table 1 Retrospective studies in which patients with advanced ovarian cancer were treated with neoadjuvant chemotherapy followed by cytoreductive surgery.

From: Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients

Authors No. of patients treated with neoadjuvant chemotherapy Main conclusion
Kuhn W et al. (8) 37 Better median survival in the group treated with neoadjuvant chemotherapy compared with the group treated with primary cytoreductive surgery
Onnis A et al. (9) 88 In 46% of operated patients, the residual tumour was < 2 cm. An improvement in the quality of surgery and disease-free period was observed, while survival rate did not improve when comparing the neoadjuvant chemotherapy group to the group that received adjuvant chemotherapy
Shimizu Y et al. (10) 74 In 46% of operated patients, the residual tumour was < 2 cm. Survival for the optimally debulked neoadjuvant chemotherapy group was significantly higher than that for the optimally debulked adjuvant chemotherapy group
Vergote I et al. (11) 75 Crude survival was higher when selecting about one-half of patients for neoadjuvant chemotherapy
Surwit E. et al. (12) 29 Median survival was 22 months
Schwartz PE et al. (13) 59 No statistical difference was observed in overall and progression-free survival between the group treated with neoadjuvant chemotherapy and the conventionally treated group
Jacob JH et al. (14) 22 The same survival as in 18 matched controls
Lim JT et al. (15) 30 Neoadjuvant chemotherapy can make patients operable
Lawton FG et al. (16) 36 78% of patients were treated with neoadjuvant chemotherapy, of whom in 89% the residual tumour was < 2 cm
Ansquer Y et al. (17) 54 Better survival of patients treated with neoadjuvant chemotherapy compared to patients with non-debulked tumours
Recchia F et al. (18) 34 Median survival was 28 months for stage IV patients
Loizzi V et al. (19) 30 Survival in the neoadjuvant and adjuvant chemotherapy groups was similar
Kayikcioglu F et al. (20) 45 Primary neoadjuvant chemotherapy followed by cytoreductive surgery did not appear to worsen the prognosis
Morice P et al. (21) 57 Survival rates were similar in patients who underwent interval debulking surgery or primary debulking surgery
Ivanov S et al. (22) 46 The five-year survival rate following the neoadjuvant chemotherapy was the same as in case of conventional chemotherapy